Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Martek, Capsugel settle, strike DHA deal

This article was originally published in The Tan Sheet

Executive Summary

After resolving a patent dispute, Capsugel agrees to purchase algae-derived DHA exclusively from Martek Biosciences. Columbia, Md.-based Martek, which filed an action for infringement against Capsugel France in November 2008, said Sept. 10 it will collaborate with the Pfizer subsidiary to add DHA to Capsugel's Licaps liquid-filled hard capsules. Martek said the patent settlement with Capsugel is not related to a separate dispute with Lonza dealing with certain patents on the life'sDHA production process (1"The Tan Sheet" Sept. 7, 2009, In Brief). After a federal appeals court ruled against Lonza in support of Martek's patents, Martek CEO Steve Dubin said Sept. 8 the firm continues to "vigorously defend its patent portfolio," which includes more than 700 granted and pending patents worldwide

Related Content

Martek looks beyond infant formulas





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts